Aptevo Therapeutics Expands Bispecific Antibody Portfolio
Based on Aptevo’s proprietary ADAPTIR™ protein therapeutic platform, the Company’s latest bispecific candidates targeting CD123 were designed to redirect T-cell cytotoxicity to CD123-expressing tumors cells, a cell surface receptor highly expressed in several hematological malignancies. Results being presented at AACR will examine the in vitro and in vivo activity of optimized lead candidates, APVO436 and APVO437, in preclinical models of acute myeloid leukemia (AML).
|Title:||Bispecific anti-CD123 x anti-CD3 ADAPTIR Molecules for Redirected T-cell Cytotoxicity in Hematological Malignancies|
|Date/Time:||April 2, 2017 – 1:00 – 5:00 pm ET|
|Session Title:||T-Cell Immunity to Cancer – New Progress (Immunology)|
Abstracts for the AACR annual meeting are available and can be viewed online at www.aacr.org. Aptevo’s poster presentation will be available on the Investor Relations section of the Company’s website at www.aptevotherapeutics.com following the poster session.
Aptevo Therapeutics Stacey JurchisonSenior Director, Investor Relations and Corporate Communications 206-859-6628 JurchisonS@apvo.com